Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Enterobiome Inc. operates in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These actions are assigned to 2 distinct examiners, meaning each pending matter is being reviewed by a different person. This requires the company to manage separate examiner interactions simultaneously within its portfolio.
Both pending actions are located within 1 distinct art unit, which indicates a high degree of technical consistency in the company's current filings. DURYEE, ALEXANDER MARSH is the busiest examiner for the portfolio, holding a busiest examiner pending count of 1. Because of this distribution, the pending office actions are split between the distinct examiners.
The concentration of pending office actions within a distinct art unit suggests that the company's Biotechnology & Pharmaceuticals innovations are being evaluated by a specific technical group. Practitioners can focus on the trends of this art unit while addressing the individual preferences of the distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.6% |
| EDWARDS, JESSICA FAYE | 1 | 39.1% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18008364 | NOVEL FAECALIBACTERIUM PRAUSNITZII STRAIN EB-FPDK9 AND USE THEREOF | EDWARDS, JESSICA FAYE | 36d overdue |
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18008364 | NOVEL FAECALIBACTERIUM PRAUSNITZII STRAIN EB-FPDK9 AND USE THEREOF | EDWARDS, JESSICA FAYE | 36d overdue |
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | 1657 | §102§103§112Other | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18008364 | NOVEL FAECALIBACTERIUM PRAUSNITZII STRAIN EB-FPDK9 AND USE THEREOF | EDWARDS, JESSICA FAYE | 1657 | §101§112 | Non-Final OA | 36d overdue | Pending | Dec 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial